“Unraveling the Clot-Miscarriage Nexus: Mechanisms, Management, and Future Directions in Thrombosis-Related Recurrent Pregnancy Loss”

Figures

• 

  Figure 1.. Mechanisms linking thrombosis and recurrent spontaneous abortion. Thrombotic factors, such as hypercoagulable states during pregnancy, placental thrombosis, inflammation, and endothelial dysfunction, contribute to the risk of RSA in pregnant women.

• 

  Figure 2.. Risk factors related to thrombosis and miscarriage. Multiple inherited or acquired factors, encompassing maternal, genetic, and environmental factors, are believed to significantly influence the occurrence of RSA.

• 

  Figure 3.. Classification of thrombophilia risk in clinical evaluation. Recognizing the thrombophilia-related risk factors in clinical assessment is essential for managing pregnancy, facilitating safe delivery, and averting complications affecting the mother and infant.

• 

  Figure 4.. Diagnostic and therapeutic approaches for thrombosis-related RSA. Clinical evaluation and laboratory screening tests for thrombophilia, including factor V Leiden, prothrombin gene mutations, and protein S deficiency, serve as essential diagnostic methods to attain a more precise diagnosis in patients with venous thromboembolism. In order to assess placental blood flow and identify potential thrombotic lesions, imaging studies, especially ultrasound and Doppler techniques, are crucial. In terms of treatment, anticoagulant medications, such as LMWH and aspirin, prevent thrombosis in patients with RSA, and combination therapies can improve the outcomes of pregnancy. Immunotherapy and other targeted treatments could assist with handling recurrent miscarriages. Additionally, new surgical techniques and other innovative therapeutic approaches have recently been developed to mitigate the adverse consequences of thrombotic events during pregnancy.